Pheochromocytoma: Presentation, diagnosis and treatment

Journal of Hypertension

Volumn 24, Issue 12, 2006, Pages 2331-2339

  Reisch, Nicole ^a   Peczkowska, Mariola ^b   Januszewicz, Andrzej ^b   Neumann, Hartmut P H ^c,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Genetic screening; Hypertensive crisis; Laparoscopic surgery; Measurement of metanephrines; Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CYCLOPHOSPHAMIDE; DACARBAZINE; DIHYDROXYPHENYLALANINE F 18; DOXAZOSIN; FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111; PRAZOSIN; RADIOISOTOPE; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMEN; ADRENAL GLAND; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HYPERTENSION; LAPAROSCOPIC SURGERY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; URINALYSIS;

EID: 33750592253     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000251887.01885.54     Document Type: Review

References (73)

1. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor. J Surg Oncol 2005; 89:193-201.
2. Yeo H, Roman S. Pheochromocytoma and functional paraganglioma. Curr Opin Oncol 2005; 17:13-18.
3. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6:477-484.
4. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459-1466.
5. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23:8812-8818.
6. Dluhy RG. Pheochromocytoma - death of an axiom. N Engl J Med 2002; 346:1486-1488.
7. Lehnert H, Hahn K, Dralle H. [Benign and malignant pheochromocytoma]. Internist (Berl) 2002; 43:196:199-209.
8. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet 2003; 361:2059-2067.
9. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 2005; 17:7-12.
10. Pawlu C, Bausch B, Reisch N, Neumann HP. Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol (Paris) 2005; 66:178-185.
11. Pawlu C, Bausch B, Neumann HP. Mutations of the SDHB and SDHD genes. Fam Cancer 2005; 4:49-54.
12. Salmenkivi K, Heikkila P, Haglund C, Arola J. Malignancy in pheochromocytomas. Apmis 2004; 112:551-559.
13. Khorram-Manesh A, Ahlman H, Nilsson O, Oden A, Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. Eur J Surg Oncol 2004; 30:556-559.
14. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004; 11:423-436.
15. Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 2004; 150:681-686.
16. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 1999; 141:619-624.
17. Plouin PF, Degoulet P, Tugaye A, Ducrocq MB, Menard J. Screening for phaeochromocytoma: in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's translation). Nouv Presse Med 1981; 10:869-872.
18. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich) 2002; 4:62-72.
19. Neumann HP, Pawlu C. Phäochromozytom und multiple endokrine Neoplasie. In: Berger DP, Engelhardt R, Mertelsmann R, editors. Das rote Buch, Hämatologie und Internistische Onkologie. Landsberg/Lech: Ecomed.
20. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427-1434.
21. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83:2175-2185.
22. Westphal SA. Diagnosis of a pheochromocytoma. Am J Med Sci 2005; 329:18-21.
23. Eisenhofer G, Rundquist B, Aneman A, Friberg P, Dakak N, Kopin IJ, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 1995; 80:3009-3017.
24. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Lond) 1995; 88:533-542.
25. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2001; 2:297-311.
26. Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005; 257:60-68.
27. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 2005; 51:735-744.
28. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86:1999-2008.
29. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004; 11:897-911.
30. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88:2656-2666.
31. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88:553-558.
32. Sawka AM, Gafni A, Thabane L, Young WF . The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 2004; 89:2859-2866.
33. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004; 89:479-491.
34. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531-1538.
35. 131I]- metaiodobenzylguanidine scintigraphy. Int J Urol 1999; 6:119-124.
36. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13:513-521.
37. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [[123]I]metaiodobenzylguanidine and [[111]In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86:685-693.
38. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:895-902.
39. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004; 25:568-580.
40. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003; 88:4083-4087.
41. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology 2002; 222:507-512.
42. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003; 30:689-694.
43. 11C hydroxyephedrine PET. Radiology 2004; 230:423-428.
44. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma. Front Horm Res 2004; 31:45-60.
45. Joerger M, Koeberle D, Neumann HP, Gillessen S. Von Hippel-Lindau disease - a rare disease important to recognize. Onkologie 2005; 28:159-163.
46. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 2000; 85:4568-4574.
47. Riegler P, Huber W, Corradini R, Neumann HP, Glaesker S, Sessa A. Von Hippel-Lindau disease: the role of gene analysis in affected families. Nephron 2000; 84:95-97.
48. Opocher G, Conton P, Schiavi F, Macino B, Mantero F. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1 Review. Fam Cancer 2005; 4:13-16.
49. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 194:629-642.
50. Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol Clin 2002; 20:841-865.
51. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292:943-951.
52. Hes FJ, Hoppener JW, Lips CJ. Clinical review 155: pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 2003; 88:969-974.
53. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91:827-836.
54. Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294:2057-2063.
55. Tauzin-Fin P, Sesay M, Gosse P, Ballanger P. Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for phaeochromocytoma. Br J Anaesth 2004; 92:512-517.
56. Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16:359-369.
57. Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 2002; 26:1037-1042.
58. Adams HA, Hempelmann G. Anesthesia for patients with pheochromocytoma. Our own results and a review. Anasthesiol Intensivmed Notfallmed Schmerzther 1993; 28:500-509.
59. Walz MK, Petersenn S, Koch JA, Mann K, Neumann HP, Schmid KW. Endoscopic treatment of large primary adrenal tumours. Br J Surg 2005; 92:719-723.
60. Walz MK, Peitgen K, Diesing D, Petersenn S, Janssen OE, Philipp T, et al. Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias. World J Surg 2004; 28:1323-1329.
61. Walz MK, Peitgen K, Neumann HP, Janssen OE, Philipp T, Mann K. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg 2002; 26:1005-1012.
62. Walz MK, Peitgen K, Walz MV, Hoermann R, Saller B, Giebler RM, et al. Posterior retroperitoneoscopic adrenalectomy: lessons learned within five years. World J Surg 2001; 25:728-734.
63. Walz MK, Peitgen K, Saller B, Giebler RM, Lederbogen S, Nimtz K, et al. Subtotal adrenalectomy by the posterior retroperitoneoscopic approach. World J Surg 1998; 22:621-626.
64. Neumann HP, Bender BU, Reincke M, Eggstein S, Laubenberger J, Kirste G. Adrenal-sparing surgery for phaeochromocytoma. Br J Surg 1999; 86:94-97.
65. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366:665-675.
66. Iihara M, Suzuki R, Kawamata A, Omi Y, Kodama H, Igari Y, et al. Adrenal-preserving laparoscopic surgery in selected patients with bilateral adrenal tumors. Surgery 2003; 134:1066-1072.
67. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004; 198:525-534.
68. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS , et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003; 134:956-962.
69. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98:239-248.
70. Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. Ann NY Acad Sci 2002; 970:54-60.
71. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109:267-273.
72. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001; 12:469-475.
73. Tada K, Okuda Y, Yamashita K. Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res 1998; 49:295-297.